Jorge Puelles
Takeda Pharmaceutical Company
21 Papers
7 Citations
Jorge Puelles is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 9, co-authored 16 publications.
Chat about Author
Papers
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.
TL;DR: High treatment failure rates associated with existing biologics, identified by the review and clinician surveys, indicate a need for other biologic treatment options to improve the management and outcomes for people with UC and CD.
Early-stage Mycosis Fungoides: Epidemiology and Prognosis.
TL;DR: The rarity of early-stage mycosis fungoides is confirmed, a differential prognosis and the potential for elevated burden of disease are confirmed, and how long patients live with late-stage disease is characterised.
37
Epidemiology of prurigo nodularis in England: a retrospective database analysis
Christopher L. Morgan,Mel Thomas,Sonja Ständer,Z.K. Jabbar‐Lopez,Christophe Piketty,Sylvie Gabriel,Craig John Currie,Jorge Puelles +7 more
TL;DR: Prurigo nodularis is a debilitating skin condition that is classified as rare by the Genetic and Rare Diseases Information Center and the National Organization for Rare Diseases (NORD).
28
Content validity of a sleep numerical rating scale and a sleep diary in adults and adolescents with moderate-to-severe atopic dermatitis.
Carla Dias-Barbosa,Rodolfo Matos,Margaret Vernon,Colleen E. Carney,Andrew D. Krystal,Jorge Puelles +5 more
TL;DR: The study supported the content validity of a sleep disturbance numerical rating scale (SD NRS) and a Consensus Sleep Diary adapted for adults and adolescents with moderate-to-severe AD and emphasized the importance of using these instruments daily when assessing the benefit of a new treatment on sleep quality.
The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis.
Dennis A. Revicki,Sara Lavoie,Rebecca M. Speck,Jorge Puelles,Braden Kuo,Michael Camilleri,Cristina Almansa,Henry P. Parkman +7 more
TL;DR: The ANMS GCSI-DD was easily understood, found to contain the most important symptoms for patients with idiopathic and diabetic gastroparesis, and no changes were recommended.
17